HRP20210361T1 - Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja - Google Patents
Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja Download PDFInfo
- Publication number
- HRP20210361T1 HRP20210361T1 HRP20210361TT HRP20210361T HRP20210361T1 HR P20210361 T1 HRP20210361 T1 HR P20210361T1 HR P20210361T T HRP20210361T T HR P20210361TT HR P20210361 T HRP20210361 T HR P20210361T HR P20210361 T1 HRP20210361 T1 HR P20210361T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical compound
- neurodegenerative disorder
- patient
- use according
- progression
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims 5
- HIZCTWCPHWUPFU-UHFFFAOYSA-N Glycerol tribenzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(OC(=O)C=1C=CC=CC=1)COC(=O)C1=CC=CC=C1 HIZCTWCPHWUPFU-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 238000000034 method Methods 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- ITRIWXSLDIKBHK-UHFFFAOYSA-N (3-benzoyloxy-2-hydroxypropyl) benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC(O)COC(=O)C1=CC=CC=C1 ITRIWXSLDIKBHK-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (7)
1. Farmaceutski spoj koji se sastoji od gliceril tribenzoata i/ili gliceril dibenzoata za uporabu u metodi za sprječavanje progresije neurodegenerativnog poremećaja, pri čemu se navedena metoda sastoji od davanja učinkovite količine navedenog farmaceutskog spoja pacijentu kojemu je liječenje potrebno.
2. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu se u navedenoj metodi farmaceutski spoj daje pacijentu jednom dnevno.
3. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu je farmaceutski spoj formuliran zajedno s farmaceutski prihvatljivim nosačem ili ekscipijensom.
4. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu se u navedenoj metodi farmaceutski spoj primjenjuje oralno.
5. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu je farmaceutski spoj za uporabu u metodi za sprječavanje progresije neurodegenerativnog poremećaja, a učinkovita količina iznosi od oko 1 grama do oko 5 grama dnevno na temelju pacijenta teškog 50 kg.
6. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu je farmaceutski spoj za uporabu u metodi za sprječavanje progresije neurodegenerativnog poremećaja, a učinkovita količina iznosi oko 1,25 grama dnevno na temelju pacijenta teškog 50 kg.
7. Farmaceutski spoj za uporabu u skladu s 1. patentnim zahtjevom, pri čemu je neurodegenerativni poremećaj odabran iz skupine koja se sastoji od multiple skleroze, Parkinsonove bolesti, Alzheimerove bolesti, Huntingtonove bolesti, demencije, poremećaja gubitka sjećanja i bilo koje kombinacije navedenih poremećaja.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| EP15737329.1A EP3094616B1 (en) | 2014-01-17 | 2015-01-16 | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210361T1 true HRP20210361T1 (hr) | 2021-04-16 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210361TT HRP20210361T1 (hr) | 2014-01-17 | 2021-03-03 | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (hr) |
| EP (1) | EP3094616B1 (hr) |
| JP (2) | JP6836905B2 (hr) |
| CA (1) | CA2936548C (hr) |
| CY (1) | CY1124115T1 (hr) |
| DK (1) | DK3094616T3 (hr) |
| ES (1) | ES2853974T3 (hr) |
| HR (1) | HRP20210361T1 (hr) |
| HU (1) | HUE053671T2 (hr) |
| LT (1) | LT3094616T (hr) |
| PL (1) | PL3094616T3 (hr) |
| PT (1) | PT3094616T (hr) |
| RS (1) | RS61611B1 (hr) |
| SI (1) | SI3094616T1 (hr) |
| WO (1) | WO2015109215A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005856A2 (pt) * | 2017-10-06 | 2020-09-29 | Rush University Medical Center | uso de uma composição contendo benzoato para tratar encefalopatia da glicina |
| MY197404A (en) * | 2017-11-22 | 2023-06-16 | Lin Chieh Hsin | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| CN113473981A (zh) * | 2019-02-25 | 2021-10-01 | 拉什大学医学中心 | 含肉桂酸的组合物以及其使用方法 |
| WO2021011500A2 (en) * | 2019-07-16 | 2021-01-21 | Rush University Medical Center | Use of a benzoate containing composition to treat neurodegenerative disorders |
| CN116390761A (zh) * | 2020-10-28 | 2023-07-04 | 拉什大学医学中心 | 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用 |
| CA3205005A1 (en) * | 2020-12-16 | 2022-06-23 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| WO2008083226A2 (en) | 2006-12-28 | 2008-07-10 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
-
2015
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en active Application Filing
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-03 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9968582B2 (en) | 2018-05-15 |
| CA2936548C (en) | 2022-08-30 |
| ES2853974T3 (es) | 2021-09-20 |
| PT3094616T (pt) | 2021-03-03 |
| CY1124115T1 (el) | 2022-05-27 |
| EP3094616A1 (en) | 2016-11-23 |
| EP3094616A4 (en) | 2017-08-23 |
| PL3094616T3 (pl) | 2021-05-31 |
| WO2015109215A1 (en) | 2015-07-23 |
| DK3094616T3 (da) | 2021-02-15 |
| CA2936548A1 (en) | 2015-07-23 |
| HUE053671T2 (hu) | 2021-07-28 |
| LT3094616T (lt) | 2021-04-12 |
| RS61611B1 (sr) | 2021-04-29 |
| US20160331714A1 (en) | 2016-11-17 |
| SI3094616T1 (sl) | 2021-07-30 |
| JP6836905B2 (ja) | 2021-03-03 |
| JP2017505811A (ja) | 2017-02-23 |
| JP2020037558A (ja) | 2020-03-12 |
| EP3094616B1 (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| JP2015057451A5 (hr) | ||
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| TN2017000226A1 (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| JP2015038135A5 (hr) | ||
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| EA201491484A1 (ru) | Фармацевтические композиции, содержащие диметилфумарат | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2017505811A5 (hr) | ||
| HRP20192235T1 (hr) | SPOJEVI KORISNI ZA INHIBITIRANJE ROR-γ-T | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| RU2016131454A (ru) | Применения витамина d и его композиций для антибиоза | |
| BR112018015851A2 (pt) | composto, e, medicamento. | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HRP20191434T1 (hr) | Liječenje eritromelalgije | |
| PE20151424A1 (es) | Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| PL3085383T3 (pl) | Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona | |
| ECSP17008187A (es) | Formas de dosificación farmacéutica |